Blastocyst transfer does not improve cycle outcome as compared to D3 transfer in antagonist cycles with an elevated progesterone level on the day of hCG

Cem Demirel1, Serkan Aydoğdu1, Arzu İlknur Özdemir1, Gülşah Keskin2, Ercan Baştu2, Faruk Buyru2
1In Vitro Fertilization Center, Memorial Ataşehir Hospital, İstanbul, Turkey
2Department of Obstetrics and Gynecology, İstanbul University School of Medicine, İstanbul, Turkey

Abstract

Objective: To evaluate the association between progesterone elevation on the day of human chorionic gonadotropin (hCG) administration and clinical pregnancy rates of gonadotropin-releasing hormone (GnRH) antagonist in vitro fertilization/intracytoplasmic sperm injection (IVF/ICSI) cycles with the transfer of embryos at different developmental stages (day-3 versus day-5 ETs).

Material and Methods: This is a retrospective analysis of fresh IVF/ICSI; 194 cycles out of 2676 conducted in a single center.

Results: A total of 2676 cycles were analyzed, of which 386 had no progesterone measurements available. Two hundred eighteen cycles had progesterone elevation (p>1.5 ng/mL) giving an overall incidence of 9.5%. Twenty-four cycles were excluded from further analysis. Of the remaining 194 cycles, 151 had day-3 transfers and 43 had blastocyst transfers. There was no statistically significant difference in pregnancy and clinical pregnancy rates per transfer between the D3-ET and D5-ET groups (46% vs. 49%, and 39% vs. 35%, respectively).

Conclusion: The results of this study suggest that blastocyst transfer does not improve cycle outcomes compared with D3 transfer in GnRH antagonist cycles with an elevated progesterone level on the day of hCG. (J Turk Ger Gynecol Assoc 2017; 18: 133-8)

Keywords: Blastocyst transfer, human chorionic gonadotropin administration, progesterone elevation

Received: 23 February, 2017 Accepted: 3 July, 2017

Introduction

Attention has been extensively paid during the last 20 years to serum progesterone measurement during ovarian stimulation. Since the early 90s, many studies have documented that a premature and excessive progesterone elevation above a certain threshold, before triggering of ovulation, might negatively affect of in vitro fertilization (IVF) outcomes (1-3). Elevated progesterone (P₄) levels in the follicular phase has been a matter of debate in terms of IVF cycle outcomes. Apart from the discrepancies in definition of “elevated P₄,” some studies claimed no effect at all (4-6), whereas others reported poorer outcomes (7-12). A favorable effect on pregnancy rates was also documented in an earlier study (13).

It was reported for the first time in 1991 that serum progesterone may increase during the last few days of ovarian stimulation (14). This has been widely confirmed during the last two decades, but the incidence of progesterone elevation greatly varies between published studies (2-35%) (15, 16). This increase does not reflect “premature luteinization”. Progesterone elevation occurs because the risk of endogenous leutinizing hormone (LH) surge is usually controlled by simultaneous administration of gonadotropin-releasing hormone (GnRH) analogues or antagonists. Progesterone elevation during ovarian stimulation is primarily related to the intensity of the ovarian response to follicle-stimulating hormone (FSH), but is also dependent on the studied population, which may consist of normal or good responders.

It has been supposed that premature elevation of P₄ advances the endometrium and leads to embryo-endometrial asynchrony. High serum P₄ levels on the day of human chorionic gonadotropin (hCG) administration induce both
advanced endometrial histologic maturation and differential endometrial gene expression, which decrease endometrial receptivity and might be related to implantation failure (17, 18). Progesterone elevation prematurely opens the window of implantation, modifies endometrium receptivity, and is associated with a defective implantation. A management strategy with robust evidence is lacking in such cycles. Postponing embryo transfers (ET) may result in better synchronization between the embryo and the already-ahead-of-phase endometrium.

Papanikolaou et al. (11) and Elgindy (9) concluded that elevated P$_4$ had a detrimental effect on day-3 but not day-5 ETs. The authors suggested that on the fifth luteal day, the endometrium had sufficiently recovered to allow for normal implantation. On the other hand, Hill et al. (19), Huang et al. (20), Corti et al. (21), and Ochsenkühn et al. (10) suggested that progesterone elevation on the day of hCG triggering had a negative impact on IVF outcomes, even with blastocyst transfers. These results were contrary to the findings of previous studies (9, 11).

The aim of our study was to evaluate the association between progesterone elevation on the day of hCG administration and clinical pregnancy rates of GnRH antagonist IVF/ICSI cycles with the transfer of embryos at different developmental stages (day-3 vs. day-5 ETs).

**Material and Methods**

**Subjects**
This is a retrospective analysis of fresh IVF/intracytoplasmic sperm injections (IVF/ICSI); 194 cycles out of 2676 conducted from January 2006 to August 2011 in a single center. The study protocol was approved by the institutional review board of the hospital; informed consent was waived due to the retrospective nature of this study.

The study inclusion criteria were: (1) GnRH antagonist cycles with a P$_4$>1.5 ng/mL on day of hCG, (2) in which ≥8 MII oocytes were retrieved and (3) at least three 8-cell embryos were present on day 3, (4) women were aged <40 years with regular cycles, (5) day-3 FSH level of <10 IU/L, antral follicle count of >5, and (6) an endometrial thickness ≥8 mm on the hCG day. Each patient was included in the study only once in the data set of the present study.

The exclusion criteria were: (1) use of frozen-thaw ETs, (2) previous history of poor ovarian response, (3) pre-implantation genetic diagnosis (PGD) cycles, (4) GnRH agonist- triggered cycles, (5) the use of testicular sperm, (6) known endocrine disorders, (7) cases where blood was drawn and analyzed in another laboratory.

The following patient characteristics were assessed: cause of infertility, age, duration of gonadotropin stimulation, E2 and P$_4$ levels on the hCG day, the numbers of oocytes retrieved, MII and 2PN fertilized oocytes, and transferred embryos.

**Controlled ovarian hyperstimulation protocol**
The GnRH antagonist protocol was initiated on day 2 of the menstrual cycle with either hMG or rFSH (Menogon, Ferring, Switzerland or Gonal F 75 IU ampules; Serono, Geneva, Switzerland; 150-300 IU/d) for ovarian stimulation. The dose was adjusted for each patient according to the follicular growth detected using ultrasonography after the 5th day of drug administration. GnRH antagonist Orgalutran (Organon, Netherlands) 0.25 mg/dL per day was started on stimulation day 5.

**Ovarian follicular development and oocyte retrieval**
When at least two follicle were ≥18 mm, 10,000 IU hCG (Pregnyl SC freeze-dried ampoule, MSD, Baxter Pharmaceutical Solutions LLC, Bloomington, USA) or 250 µgr of rec-hCG (Ovitrelle, Serono, Germany) was administered to trigger ovulation.

Oocyte retrieval was performed at hour 35 after hCG injection. An oocyte pick-up was completed using a 17-gauge needle for oocyte retrieval under local anesthesia. The oocyte–corona complexes were denuded, intracytoplasmic sperm injection was performed after 2 hours of incubation, and embryos were transferred on days 3 or 5.

**Embryo transfer and luteal phase support**
The fertilized oocytes were observed for morphology on day 3. One hundred fifty-one participants underwent ET on day 3 (D3-ET), and 43 underwent ET on day 5 (D5-ET) because there was an adequate number of high-quality embryos available. Only high-quality embryos were transferred both on D3-ET and D5-ET. The choice of the ET day was mainly based on the embryo morphology, clinicians’ preference for cryopreservation of spare embryos on day 3, and workload of the laboratory. Embryologists graded embryos as good, fair, or poor in line with the simplified Society for Assisted Reproductive Technology scoring system (22).

Both groups were tested for serum βhCG 12 days after ET and transvaginal ultrasound was scheduled 3 weeks afterwards to confirm clinical pregnancy. The luteal phase was supported with intravaginal micronized progesterone (Progestan 200 mg; Koçak, Tekirdağ, Turkey) as 600 mg/day, starting on the day of oocyte retrieval.

**Hormonal evaluation**
On the day of hCG trigger, serum P$_4$ and E2 levels were measured on a blood sample drawn at 10:00 AM. We used a microparticle enzyme immunoassay (Axsym System; Advia Centaur, Siemens), which has a sensitivity of 0.21 ng/mL. For the
P₄ assay, the intra- and interassay coefficients of variation are 7.2% and 5.7%, respectively. The E₂ assay has a sensitivity of 7.0 pg/mL, with intra- and interassay coefficients of variability of 11.3% and 5.0%, respectively. We selected a serum progesterone level of 1.5 ng/mL on the day of hCG administration as a cutoff level for an adverse cycle outcome as evidenced by the literature (9).

**Evaluation of in vitro fertilization/intracytoplasmic sperm injection results**

Clinical pregnancy and early pregnancy loss rates of D3-ET and D5-ET groups were evaluated. Clinical pregnancy rate was the primary outcome. Clinical pregnancy was defined as the presence of a gestational sac on transvaginal sonography.

**Statistical analysis**

The statistical analysis of the study was performed using the Statistical Package for the Social Sciences 20.0 (SPSS Inc., Chicago, IL, USA) and G*Power 3 (Düsseldorf, Germany) (23). Categorical variables in the data set are given with frequencies and percentages, but the continuously changing variables are given with mean, standard deviation, median, minimum and maximum values. The compliance of the measurement variables with normal distribution was analyzed using the Shapiro-Wilk test. In the comparison of two groups of variables with normal distribution, the difference between the two means was determined using the significance test (t test), and the comparison of variables that do not show normal distribution was performed using the Mann-Whitney U test. In the comparison of categorical variables between groups, Yates’s corrected Chi-square test was used. In all the statistical analyses in the study, comparisons under a p-value of 0.05 were considered statistically significant.

**Results**

A total of 2676 cycles were analyzed, of which 386 had no progesterone measurements available. Two hundred eighteen cycles were noted to have progesterone elevation (p>1.5 ng/mL) giving an overall incidence of 9.5%. Twenty-one cycles were excluded from further analysis because there were fewer than three 8-cell embryos on day 3 or no blastocysts on day 5. Three additional cycles were excluded because of total embryo freezing and no fresh ET in the given cycle. Of the remaining 194 cycles, 151 had day-3 transfers, and 43 had blastocyst transfers. There was no statistically significant difference in the demographics between the two study groups (Table 1).

The mean age of D3-ET group was 30.65±4.12 years (range, 19-40 years), and that of the D5-ET group was 29.9±3.07 years (range, 22-36 years). Both groups had a similar duration of controlled ovarian hyperstimulation. The mean level of serum progesterone on the day of hCG administration was 1.83±0.49 ng/mL in the D3-ET group and 1.92±0.87 ng/mL in the D5-ET group (p>0.05). The D5-ET group had a significantly higher mean estradiol level on the day of hCG (3940.7±1928.20 vs. 2803.62±1639.73 pg/mL, p=0.001). The mean number of oocytes retrieved was significantly higher (22.23±8.93 vs. 15.63±7.76, p=0.001) in the D5-ET group, along with a higher number of MII (17.1±6.75 vs. 10.86±5.86, p=0.001) and 2PN fertilized oocytes (13.33±5.03 vs. 7.81±4.59, p=0.001), respectively. There was no statistically significant difference in the mean number of embryos transferred in the day 3 and day 5 groups (2.2 vs. 1.8, respectively) (Table 2).

There was no statistically significant difference in pregnancy and clinical pregnancy rates per transfer between the D3-ET and D5-ET groups (46% vs. 49%, and 39% vs. 35%, respectively) (Figure 1).

### Table 1. Patient overview

| D3-ET | D5-ET | p     |
|-------|-------|-------|
| Age, years | 30.65±4.12 | 29.9±3.07 | NS |
| BMI, kg/m² | 27.32±3.16 | 28.7±3.84 | NS |
| Infertility period, years | 4.62±3.30 | 3.63±2.46 | NS |
| Day 3 FSH, mIU/mL | 6.48±2.30 | 6.28±2.10 | NS |
| Day 3 E₂, pg/mL | 38.52±10.59 | 43.59±20.15 | NS |
| Previous IVF trials, n | 0.74±1.1 | 0.76±1.01 | NS |
| Type of infertility | | | |
| Primary infertility, % | 87 | 74 | NS |
| Secondary infertility, % | 13 | 26 | NS |
| Diagnosis | | | |
| Male factor | 65 (43%) | 20 (46%) | NS |
| Unexplained infertility | 37 (25%) | 8 (18%) | NS |
| Endometriosis | 20 (14%) | 6 (14%) | NS |
| Tubal factor | 10 (6%) | 3 (7%) | NS |
| PCOS | 14 (9%) | 4 (9%) | NS |
| Others | 5 (3%) | 2 (6%) | NS |

**ET:** embryo transfer; **BMI:** body mass index; **FSH:** follicle-stimulating hormone; **IVF:** in vitro fertilization; **PCOS:** polycystic ovary syndrome; **D3-ET:** embryo transfer on day 3; **D5-ET:** embryo transfer on day 5; **E₂:** estradiol; **NS:** not significant

### Table 2. Cycle parameters in D3–ET and D5–ET groups in patients with P₄ > 1 ng/mL on the day of hCG

|        | D3-ET (n=151) | D5-ET (n=43) | p     |
|--------|---------------|--------------|-------|
| Ovarian stimulation, days | 8.95±1.6 | 9.0±1.55 | NS |
| E₂ on hCG day, pg/mL | 2803.62±1639.73 | 3940.7±1928.20 | 0.001 |
| P₄ on hCG day, ng/mL | 1.83±0.49 | 1.92±0.87 | NS |
| Oocytes retrieved, n | 15.63±7.76 | 22.23±8.93 | 0.001 |
| MII, n | 10.86±5.86 | 17.1±6.75 | 0.001 |
| 2PN, n | 7.81±4.59 | 13.33±5.03 | 0.001 |
| Embryos transferred, n | 2.2±0.5 | 1.8±0.8 | NS |

**D3-ET:** embryo transfer on day 3; **D5-ET:** embryo transfer on day 5; **ET:** embryo transfer; **hCG:** human chorionic gonadotropin; **E₂:** estradiol; **P₄:** progesterone; **MII:** metaphase II; **PN:** pronucleus; **NS:** not significant
In the present study, D5 transfer was not found to be superior
to D3 transfer of embryos in patients with elevated P₄ levels,
respectively, when the cutoff level for P₄ was set at 1.5 ng/mL
on the day of hCG administration.

Elevated P₄ in the late follicular phase of an IVF cycle is claimed
to result in worse cycle outcomes. This negative effect is
believed to be more prevalent in cycles with a higher oocyte
yield; such a negative effect may ensue with a relatively higher
P₄ elevation. It is more likely that the elevated P₄ levels reflect
the total amount of progesterone secreted by maturing follicles,
and these levels have been found to correlate positively with
the number of mature follicles and with estradiol levels on hCG
day. In the present study, we also documented an increase in E2
levels in correlation with number of mature follicles. Although
non-significant, P₄ levels were slightly elevated in the D5-ET
group, in which the number of oocytes was significantly higher.
The first attempt to critically evaluate the existing literature
regarding P₄ elevation on the day of hCG and its role in
pregnancy achievement was published in 2007 (6). The results
of that review were confounded by the different GnRH analogue
protocols administered. Moreover, the majority of the included
studies that failed to demonstrate a negative association used
an arbitrarily defined threshold value of 0.9 ng/mL. Following
that meta-analysis, a prospective study by Elgindy (9) claimed
that an increased P₄ level of ≥1.5 ng/mL on hCG day was
associated with an adverse effect on clinical outcomes. A
meta-analysis of Kolibianakis et al. (24) evaluated the results of
five eligible studies of GnRH antagonist cycles. They reported
that women with elevated P₄ level on the hCG administration
day had decreased probability of clinical pregnancy per cycle.

Another meta-analysis of Venetis et al. (16) provided convincing
data that elevation of serum P₄ secretion was associated with
low pregnancy rates whatever the GnRH analogue used. A
very recent meta-analysis that reviewed only antagonist cycles
documented that women with elevated P₄ levels >1.5 ng/
ml on hCG day had more oocytes and higher E2, as well as
decreased probability of pregnancy per cycle (25).

The crucial question is how should physicians manage patients
with elevated progesterone levels during late follicular phase.
Proposed cycle management strategies in the event of high P₄
on the day of hCG may be to freeze all embryos and transfer
them back in a natural or hormone-replacement cycle, to favor
a D5 ET, to start with a lower FSH dose in the next cycle, to use
hp-hMG instead of rFSH, and/or earlier administration of hCG
for triggering final oocyte maturation in high-risk patients. None
of the aforementioned strategies have been tested so far for
their efficacy in this setting.

For women with an elevated P₄ level on the day of hCG,
extending culture and transferring embryos on D5 might have
been a sound strategy because the most probable mechanism
of impairment that high P₄ in the follicular phase causes is the
advancement of endometrial maturation and early closure of
the endometrial implantation window; day-5 ET may restore
this asynchronization in such cycles. In several studies it is claimed that endometrial advancement
due to controlled ovarian hyperstimulation and raised P₄ could
be recovered on day 5 (26). Papanikolaou et al. (11) designed a
study to determine if there was an effect of elevated P₄ on hCG
day on pregnancy outcomes, and whether this effect might
be associated with the developmental stage of the embryo
transferred. According to this study, even modest rises of P₄ in
the follicular phase has a detrimental effect on the implantation
potential of good-quality cleavage stage embryos (11). On the
contrary, premature luteinization in the blastocyst transfer
subgroup had no effect on pregnancy outcomes.

Hill et al. (19) confirmed the recent publications by
demonstrating a negative impact of elevated serum P levels
on the day of hCG administration on live birth. This negative effect
was also demonstrated in both cleavage and blastocyst stage
ETs for both poor and good embryos. Huang et al. (20) reported
that the negative association of P₄ elevation with clinical
pregnancy rates was noted both in D-3 and blastocyst stage
ET cycles and confirmed decreased clinical pregnancy rates in
GnRH agonist IVF/ICSI cycles regardless of the developmental
stage of the transferred embryos. Ochsenkühn et al. (10)
documented a similar reduction in pregnancy rates in the study
of blastocyst transfers. However, their study had no cohort of
cleavage embryos to use for direct comparison. Corti et al.
(21) and Ochsenkühn et al. (10) suggested that progesterone
elevation on the day of hCG triggering has a negative impact
on IVF outcomes, even with blastocyst transfers. These results
were contrary to the findings of Papanikolaou et al. (11). The
study of Papanikolaou addressed whether the adverse effect of
follicular phase P₄ elevation could be alleviated by a blastocyst
transfer. In contrast to what this retrospective study suggested, in our data set, D5 transfer was not found as superior to D3 transfer of good quality embryos in patients with elevated P_4 levels. Our study was retrospective in design but, the inclusion criteria enabled us to select patients with a cohort of good quality embryos on day 3 that might have a good chance of D5 transfer if they had been allowed to stay in extended culture. Thus, the two transfer groups presented a similar embryo development profile in culture. The reason for the lack of efficiency of D5 transfer strategy may be the fact that the advanced endometrium may still have not recovered from the action of elevated follicular P_4. To our knowledge, there is no solid biologic evidence to confirm this endometrial recovery with concomitant D3 and D5 endometrial biopsies. The choice of 1.5 ng/mL as a threshold level for P_4 in our study is less than ideal because the threshold for poor cycle outcomes may change with the ovarian response of the patient. In better responders, a higher P_4 threshold is more plausible. As such, the reason for failure of observing improved outcomes with a D5 ET strategy in our study may be that our patient population comprised either normal or good responder patients and thus a higher threshold could have revealed a positive treatment effect in favor of D5 transfer. The strongest effect of progesterone elevation on pregnancy rates was observed between 1.5 and 1.75 ng/mL in the study of Venetis et al. (16). Nevertheless, as the degree of ovarian response is increased, the failure of a beneficial effect for D5 ETs still may persist. In poor responders with an elevated P_4 level, the management strategy could have been to freeze all embryos rather than to try a D5 transfer due to the lack of availability of an adequate number of embryos for extended culture.

The limitation of our study is its retrospective nature; this kind of study has selection bias. Also, the number of D5 transfers was lower than that of D3, which also weakened the study power. In conclusion, the results of this retrospective study suggest that blastocyst transfer does not improve cycle outcomes as compared with D3 transfer in GnRH antagonist cycles with an elevated progesterone level on the day of hCG. Therefore, a prospective randomized control trial on an intention-to-treat basis is needed to compare single D3 and single blastocyst transfers in this setting to reach a more definitive answer to the problem.

Acknowledgement: We would like to thank Mr. David F. Chapman, Bsc (BioMedical Sciences), for editing the language of the manuscript.

Ethics Committee Approval: Ethics committee approval was received for this study from the ethics committee of IVF Center, Memorial Atasehir Hospital, Istanbul, Turkey.

Informed Consent: Written informed consent was obtained from patients who participated in this study.

Peer-review: Externally peer-reviewed.

Author Contributions: Concept – C.D., S.A., A.İ.Ö., G.K., E.B., F.B.; Design – C.D., S.A., A.İ.Ö., G.K.; Supervision – C.D., S.A., A.İ.Ö., G.K.; Materials – C.D., S.A., A.İ.Ö., G.K.; Data Collection and/or Processing – C.D., S.A., A.İ.Ö.,...; Analysis and/or Interpretation - C.D., S.A., A.İ.Ö.; Literature Review – C.D., S.A., A.İ.Ö., G.K., E.B.; Writer - C.D., S.A., A.İ.Ö., G.K., E.B., F.B.; Critical Review - C.D., S.A., A.İ.Ö., G.K., E.B., F.B.

Conflict of Interest: No conflict of interest is declared by the authors.

Financial Disclosure: The authors declared that this study received no financial support.

References

1. Fanchin R, de Ziegler D, Taieb J, Hazout A, Frydman R. Premature elevation of plasma progesterone alters pregnancy rates of in vitro fertilization and embryo transfer. Fertil Steril 1993; 59: 1090-4.

2. Fanchin R, Righini C, Olivennes F, Ferreira AL, de Ziegler D, Frydman R. Consequences of premature progesterone elevation on the outcome of in vitro fertilization: insights into a controversy. Fertil Steril 1997; 68: 799-805.

3. Harada T, Yoshida S, Katagiri C, Takao N, Ikenari T, Toda T, et al. Reduced implantation rate associated with a subtle rise in serum progesterone concentration during the follicular phase of cycles stimulated with a combination of a gonadotrophin-releasing hormone agonist and gonadotrophin. Hum Reprod 1995; 10: 1060-4.

4. Martinez F, Coroleu B, Chua E, Tur R, Buxaderas R, Parera N, et al. Serum progesterone concentrations on the day of hCG administration cannot predict pregnancy in assisted reproduction cycles. Reprod Biomed Online 2004; 8: 183-90.

5. Seow KM, Lin YH, Huang LW, Hsieh BC, Huang SC, Chen CY, et al. Subtle progesterone rise in the single-dose gonadotrophin-releasing hormone antagonist (cetrorelix) stimulation protocol in patients undergoing in vitro fertilization or intracytoplasmic sperm injection cycles. Gynecol Endocrinol 2007; 23: 338-42.

6. Loutradi KE, Kolibianakis EM, Venetis CA, Papanikolaou EG, Pados G, Bontis I, et al. Cryopreservation of human embryos by vitrification or slow freezing: a systematic review and meta-analysis. Fertil Steril 2008; 90: 186-93.

7. Andersen AN, Devroey P, Arce JC. Clinical outcome following stimulation with highly purified hMG or recombinant FSH in patients undergoing IVF: a randomized assessor-blind controlled trial. Hum Reprod 2006; 21: 3217-27.

8. Bosch E, Labarta E, Crespo J, Simón C, Remohí J, Jenkins J, et al. Circulating progesterone levels and ongoing pregnancy rates in controlled ovarian stimulation cycles for in vitro fertilization: analysis of over 4000 cycles. Hum Reprod 2010; 25: 2092-100.

9. Elgindy EA. Progesterone level and progesterone/estradiol ratio on the day of hCG administration: detrimental cutoff levels and new treatment strategy. Fertil Steril 2011; 95: 1639-44.

10. Ochsenkühn R, Arzberger A, von Schönfeldt V, Gallwas J, Rogenhofer N, Crispin A, et al. Subtle progesterone rise on the day of human chorionic gonadotropin administration is associated with lower live birth rates in women undergoing assisted reproductive technology: a retrospective study with 2,555 fresh embryo transfers. Fertil Steril 2012; 98: 347-54.
11. Papanikolaou EG, Kolibianakis EM, Pozzobon C, Tank P, Tournaye H, Bourgain C, et al. Progesterone rise on the day of human chorionic gonadotropin administration impairs pregnancy outcome in day 3 single-embryo transfer, while has no effect on day 5 single blastocyst transfer. Fertil Steril 2009; 91: 949-52.

12. Bjelic-Radisic V, Jensen PT, Vlasic KK, Waldenstrom AC, Singer S, Chie W, et al. Quality of life characteristics inpatients with cervical cancer. Eur J Cancer 2012; 48: 3009-18.

13. Doldi N, Marsiglio E, Destefani A, Gessi A, Merati G, Ferrari A. Elevated serum progesterone on the day of HCG administration in IVF is associated with a higher pregnancy rate in polycystic ovary syndrome. Hum Reprod 1999; 14: 601-5.

14. Schoolcraft W, Sinton E, Schlenker T, Huynh D, Hamilton F, Meldrum DR. Lower pregnancy rate with premature luteinization during pituitary suppression with leuprolide acetate. Fertil Steril 1991; 55: 563-6.

15. Papanikolaou EG, Pados G, Grimbizis G, Bili E, Kyriazi L, Polyzos NP, et al. GnRH-agonist versus GnRH-antagonist IVF cycles: is the reproductive outcome affected by the incidence of progesterone elevation on the day of HCG triggering? A randomized prospective study. Hum Reprod 2012; 27: 1822-8.

16. Venetis CA, Kolibianakis EM, Bosdou JK, Tarlatzis BC. Progesterone elevation and probability of pregnancy after IVF: a systematic review and meta-analysis of over 60 000 cycles. Hum Reprod Update 2013; 19: 433-57.

17. Labarta E, Martínez-Conejero JA, Alamá P, Horcajadas JA, Pellicer A, Simón C, et al. Endometrial receptivity is affected in women with high circulating progesterone levels at the end of the follicular phase: a functional genomics analysis. Hum Reprod 2011; 26: 1813-25.

18. Van Vaerenbergh I, Fatemi HM, Blockeel C, Van Lommel L, In’t Veld P, Schuit F, et al. Progesterone rise on HCG day in GnRH antagonist/ rFSH stimulated cycles affects endometrial gene expression. Reprod Biomed Online 2011; 22: 263-71.

19. Hill MJ, Royster GD 4th, Healy MW, Richter KS, Levy G, DeCherney AH, et al. Are good patient and embryo characteristics protective against the negative effect of elevated progesterone level on the day of oocyte maturation? Fertil Steril 2015; 103: 1477-84.e1-5.

20. Huang Y, Wang Y, Du QY, Xiong YJ, Guo XY, Yu YP, et al. Progesterone elevation on the day of human chorionic gonadotropin administration adversely affects the outcome of IVF with transferred embryos at different developmental stages. Reprod Biol Endocrinol 2015; 13: 82.

21. Corti L, Papaleo E, Pagliardini L, Rabellotti E, Molgara M, La Marca A, et al. Fresh blastocyst transfer as a clinical approach to overcome the detrimental effect of progesterone elevation at hCG triggering: a strategy in the context of the Italian law. Eur J Obstet Gynecol Reprod Biol 2013; 171: 73-7.

22. Heitmann RJ, Hill MJ, Richter KS, DeCherney AH, Widra EA. The simplified SART embryo scoring system is highly correlated to implantation and live birth in single blastocyst transfers. J Assist Reprod Genet 2013; 30: 563-7.

23. Faul F, Erdfelder E, Buchner A, Lang AG. Statistical power analyses using G*Power 3.1: tests for correlation and regression analyses. Behav Res Methods 2009; 41: 1149-60.

24. Kolibianakis EM, Venetis CA, Bonits J, Tarlatzis BC. Significantly lower pregnancy rates in the presence of progesterone elevation in patients treated with GnRH antagonists and gonadotrophins: a systematic review and meta-analysis. Curr Pharm Biotechnol 2012; 13: 464-70.

25. Griesinger G, Mannaaerts B, Andersen CY, Witjes H, Kolibianakis EM, Gordon K. Progesterone elevation does not compromise pregnancy rates in high responders: a pooled analysis of in vitro fertilization patients treated with recombinant follicle-stimulating hormone/gonadotropin-releasing hormone antagonist in six trials. Fertil Steril 2013; 100: 1622-8.e1-3.

26. Fleming R, Jenkins J. The source and implications of progesterone rise during the follicular phase of assisted reproduction cycles. Reprod Biomed Online 2010; 21: 446-9.